...
首页> 外文期刊>American Journal of Translational Research >Sequential treatment of chronic obstructive pulmonary disease concurrent with respiratory failure by high-flow nasal cannula therapy
【24h】

Sequential treatment of chronic obstructive pulmonary disease concurrent with respiratory failure by high-flow nasal cannula therapy

机译:高流量鼻腔套管治疗呼吸衰竭慢性阻塞性肺病的顺序治疗

获取原文
           

摘要

Objective: To analyze the efficacy of sequential treatment with high-flow nasal cannula (HFNC) in chronic obstructive pulmonary disease (COPD) concomitant with respiratory failure. Methods: A total of 100 COPD patients concomitant with respiratory failure requiring invasive mechanical ventilation from June 2019 to May 2020 in our hospital were enrolled and then divided into two groups according to the random number table, with 50 in each group. Pulmonary infection control window (PIC) was used as a switching point for sequential ventilation. The control group (CNG) received non-invasive positive pressure ventilation (NIPPV), while the study group (SG) underwent HFNC. The efficacy, complications and 48 h reintubation rate of the two groups were statistically analyzed. The respiratory parameters, diaphragmatic parameters, diaphragmatic excursion during quiet breathing (DEq), diaphragmatic rapid shallow breathing index (D-RSBI), COPD score (CAT), 6-min walk test (6 MWT) score (Borg), General Comfort Questionnaire (GCQ), sputum viscosity, and serum factors were observed before intubation and after 48 hours of intubation. Results: The overall response rate (94.00%) in SG was higher than that in CNG (80.00%) ( P 0.05); SG had lower RR, PaCO 2 and D-RSBI at 48 hours after extubation and higher PaO 2 /FiO 2 and DEd than CNG ( P 0.05); SG exhibited lower CAT and Borg at 48 hours after extubation and higher GCQ score than CNG ( P 0.05); SG had lower sputum viscosity at 48 hours after extubation than CNG ( P 0.05); SG showed lower ET-1, NLR and NT-proBNP levels at 48 hours after extubation than CNG ( P 0.05). Conclusion: HFNC sequential therapy is effective and safe in the treatment of COPD concomitantly with respiratory failure. It can improve respiratory function and diaphragmatic function, reduce dyspnea and fatigue, reduce sputum viscosity, regulate serum factors, and make patients enjoy higher comfort.
机译:目的:分析顺序治疗与高流量鼻腔插管(HFNC)在慢性阻塞性肺病(COPD)伴随呼吸衰竭的疗效。方法:共有100名COPD患者伴随着从2019年6月到2020年5月的呼吸衰竭,从2019年6月到2020年在我们的医院注册,然后根据随机数表分为两组,每组50个。肺部感染控制窗口(PIC)用作顺序通气的开关点。对照组(CNG)接受了非侵入性阳性压力通气(NIPPV),而研究组(SG)接受了HFNC。两组的疗效,并发症和48小时重新涂布率在统计学上分析。呼吸参数,膈肌参数,​​膈肌游览在安静呼吸(DEQ),膈肌快速呼吸指数(D-RSBI),COPD得分(CAT),6分钟步行检测(6 MWT)得分(Borg),一般舒适调查问卷(GCQ),痰液粘度和血清因子在插管前观察到,在插管48小时后。结果:SG中的总反应率(94.00%)高于CNG(80.00%)(P <0.05);在拔管和更高的PAO 2 / FIO 2和CNG后48小时后,SG在48小时内具有较低的RR,PACO 2和D-RSBI(P <0.05); SG在拔管后48小时显示下猫和博格,比CNG更高的GCQ得分(P <0.05); SG在拔管后48小时的痰粘度低于CNG(P <0.05); SG在拔管后48小时显示比CNG的48小时,SG(P <0.05)在48小时内显示出较低的ET-1,NLR和NT-PROPNP水平。结论:HFNC顺序治疗在伴随着呼吸衰竭的治疗方面是有效和安全的。它可以改善呼吸功能和膈肌功能,减少呼吸困难和疲劳,减少痰粘度,调节血清因子,使患者享受更高的舒适度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号